Vernalis Share Discussion Threads

[columb0] 01/5/2009 11:00

Hi, new to this site.

Trjan - I was just wondering why the share price would go down post-decent news. Surely the brokers and major investors involved in this open offer are only agreeing to it because they know positive news is on the way which would force the price up, and compensate for the dilution. That would explain why the share price has increased recently.

What do you think?

[bountyhunter] 01/5/2009 08:49

I did the same Trojan for the same reasons, been bitten twice here, never again!

[trojan] 01/5/2009 08:01

The risk you have with this placing, after the dilution of additional shares, is the consolidation!!

If the company does put out some decent news then the share price can/will once again move down and it will have further to drop than the current level.

Let's wait and see, I reduced over the last two day's and took advantage of the 4.3p bid that was being offered!!

[4screws] 30/4/2009 19:02

vow...many thanks...sorry if I asked a stupid question but was not sure.

[vow] 30/4/2009 18:58

You will be diluted by the fact that there are 800m new shares, but consolidation itself does not dilute as all that will happen is that you will have 500 x 80p = £400. i.e one side is divided by 20 and the other multiplied by 20.

[4screws] 30/4/2009 18:50

does consolidation mean that for every 20 shares we have , we recieve 1 diluted share thus reducing the value of our holding...e.g. 10000 x 4p =£400. new value 10000 divided by 20 =500 x4 =£20 therefore losing £380.

[vow] 29/4/2009 10:05

It's only three quarters of a billion shares:-)

[trojan] 29/4/2009 09:29

It's tough to get this away in the current climate, but it's fully underwritted and I think they know they will be in a better position to increase shareholder value over the med/long term with it in place imo!!

My concern is the consolidation after the placing, which allows for the share price to drop lower than the 3p placing (post consolidation) level if the markets don't start to settle.

If's, but's and maybe's!! ;)

[fhmktg] 29/4/2009 08:57

It either suggests Fellner has strong belief in the pipeline ( supported by directors taking up their allotments) or that nobody wants the pipe?

On balance, despite having lost so much I might just back him!

[trojan] 29/4/2009 07:49

Interesting!!

[in despair sybil] 11/4/2009 12:30

not posted for a while - nice to see 4 back to back weekly gains - nice and steady too, not stretching too far outside of the bollingers.

short term trend could well be changed to upside as the golden cross rule comes into play when the 20 day MA crosses the 50 day MA to the upside, and more importantly when the 50 day MA crosses the 200 day MA to the upside.

should be an interesting couple of weeks leading into and beyond results.

expecting a little cosolidation over next couple of sessions then the rise to continue. and the lemmings haven't even yet jumped onboard.



bestest

IDS

[trojan] 04/4/2009 08:45

You and me both, although 15p would give me a very nice profit of nearly 100%!!!

[latifs100] 02/4/2009 18:06

how much cash they go tleft now.. cud do with 15p to bail out

[fhmktg] 27/3/2009 09:10

First 'Green Shoot' of spring for Vernalis.
An update on the treatment for stroke is due as well -with possible licensing at this stage of development.

Around 25th April for the interim results and closed season report?

[trojan] 27/3/2009 07:12

I don't think this is enough to re-launch the share just yet but positive news which is the main thing imo!

[lyceeuk] 27/3/2009 07:10

TIDMVER

RNS Number : 5667P
Vernalis PLC
27 March 2009

?


27 March 2009


Biogen Idec reports favourable data from Phase IIa Parkinson's Disease
studies of BIIB014 (licensed from Vernalis)


WINNERSH, U.K., 27 March 2009 Vernalis plc (LSE: VER) today announced that
Biogen Idec (NASDAQ: BIIB), presented headline data at its 25 March 2009 R&D Day
from two Phase IIa studies of BIIB014 (also known as V2006), an oral
compound for the treatment of Parkinson's disease.


In a press release, Biogen Idec announced that interim results from these Phase
IIa studies of BIIB014 were favorable and support continued development of
BIIB014 in patients with Parkinson's disease. Biogen Idec also announced that it
is currently in discussion with regulators surrounding the design of a
registration program of BIIB014 in this patient population. In a presentation
at its R&D Day, Biogen Idec reported that BIIB014 was well tolerated and showed
dose dependent clinically relevant effects in patients with both early and late
stage Parkinson's disease.


In June 2004, Vernalis entered into an agreement with Biogen Idec to develop and
commercialise BIIB014. Biogen Idec is conducting and funding future development
and will pay milestones and royalties on the successful development and
commercialisation of the product.


BIIB014 is a once-daily oral adenosine A2A receptor antagonist that may offer a
non-dopaminergic therapy for patients with Parkinson's disease.




Ian Garland, CEO of Vernalis commented:


"We are delighted that Biogen Idec has announced favourable Phase IIa data for
BIIB014 and that these data support continued development of this novel compound
as a treatment for patients with Parkinson's disease. I am pleased that this
compound, discovered by Vernalis, has the potential to be a novel,
non-dopaminergic treatment option for the very many people with Parkinson's
disease "


Access the Biogen IDEC presentation
at:

BE-5BE4-47F0-A030-17858A19C307_6_BIIB014v2.pdf






=- ends --

Enquiries:
+-----------+--------------+
| Vernalis | +44 |
| Contacts | (0) |
| | 118 977 3133 |
+-----------+--------------+
| Ian | |
| Garland, | |
| Chief | |
| Executive | |
| Officer | |
+-----------+--------------+
| David | |
| Mackney, | |
| Chief | |
| Financial | |
| Officer | |
+-----------+--------------+
| | |
+-----------+--------------+
| Brunswick | +44 |
| Group | (0) 20 |
| | 7404 5959 |
+-----------+--------------+
| Jon | |
| Coles | |
+-----------+--------------+
| Justine | |
| McIlroy | |
+-----------+--------------+
| | |
+-----------+--------------+


Notes to Editors


About Parkinson's Disease
It is estimated that between 800,000 and 1 million people in the U.S. have
Parkinson's disease, a condition that results from selective degeneration of an
area of the brain called the substantia nigra, which is located towards the base
of the brain in the basal ganglia. Normally these nerve cells release dopamine -
a chemical that transmits signals between nerve cells (called a
neurotransmitter). This central signalling pathway is essential for the fine
control of movement and posture, and breakdown results in the symptoms of
Parkinson's disease namely tremor, rigidity, slow movements and postural
instability. Muscle rigidity can become so severe as to result in "freezing"
also referred to as "off" episodes, when patients are rendered immobile.
Patients also suffer from problems relating to impaired control of blood
pressure (postural hypotension) and gut motility, which can impair the
absorption of food and drugs. The disease is progressive and the signs and
symptoms generally worsen over time. However, while Parkinson's disease may
eventually be disabling, the disease often progresses gradually and with
appropriate treatment many patients have a number of years of productive life
after initial diagnosis.


About Biogen Idec
Biogen Idec creates new standards of care in therapeutic areas with high unmet
medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery,
development, manufacturing and commercialization of innovative therapies.
Patients in more than 90 countries benefit from Biogen Idec's significant
products that address diseases such as lymphoma, multiple sclerosis and
rheumatoid arthritis. For product labeling, press releases and additional
information about the company, please visit www.biogenidec.com.


About Vernalis
Vernalis is a pharmaceutical company with expertise in both
structure-based drug discovery and pre-clinical and clinical drug development.
The company has six products in clinical trials (two of which are partnered) and
three programmes in pre-clinical trials (two with partners). Our collaborations
are with leading, global pharmaceutical companies including Biogen
Idec, Novartis, Servier, Chiesi, Menarini and Endo.

For further information about Vernalis, please visit www.vernalis.com.

Forward-Looking Statement
This news release may contain forward-looking statements that reflect the
Company's current expectations regarding future events including the clinical
development and regulatory clearance of the Company's products, the Company's
ability to find partners for the development and commercialisation of its
products, as well as the Company's future capital raising activities.
Forward-looking statements involve risks and uncertainties. Actual events could
differ materially from those projected herein and depend on a number of factors
including the success of the Company's research strategies, the applicability of
the discoveries made therein, the successful and timely completion of clinical
studies, the uncertainties related to the regulatory process, the ability of the
Company to identify and agree beneficial terms with suitable partners for the
commercialisation and/or development of its products, as well as the achievement
of expected synergies from such transactions, the acceptance of Frova and other
products by consumers and medical professionals, the successful integration of
completed mergers and acquisitions and achievement of expected synergies from
such transactions, and the ability of the Company to identify and consummate
suitable strategic and business combination transactions.



This information is provided by RNS
The company news service from the London Stock Exchange
END

MSCZGGZFVVVGLZM

[fhmktg] 18/3/2009 11:28

Mid April for the results, but a review of V10153 for stroke (Phase IIa) was promised for early 2009. Could be a further trial or even a licence?

[99damo] 18/3/2009 11:07

some good news leaking??

[fhmktg] 17/3/2009 17:18

Somebody risked £10000 buying today.
Bring 'em on!

[pugg1ey] 04/3/2009 13:08

I think they were putting lots of money into furnace 1 but found that wasn't large enough so now they've switched to furnace 2 which can take a lot more cash.

[fhmktg] 03/2/2009 14:49

This has gone VERY quiet!

Any news due?
Anybody got ideas as to what's happening?

[trojan] 30/12/2008 10:28

Probably on the PLUS market then or even VirtX????

It seems that someone has been buying these and tucking them away, should get a good return from this level imo!!

[4screws] 29/12/2008 21:56

trojan bought another £500. worth today but the trade has not shown on advfn

[trojan] 29/12/2008 16:55

Thought about doing the same, but will hold back for a min!!

Another 1.375p for my break even, but still believe this will hit 10p and you just never know it may happen for next xmas!! ;)

[4screws] 29/12/2008 16:13

only another 15p before i break even, topped up with a fewe more this aft